Placebos, Blinding and Controls in Clinical Trials Explained

Clinical trials are the careful scientific process used to determine whether a new medicine is safe and effective. To confidently prove that a drug actually works, researchers must design studies that minimise bias and separate the drug's true biological effects from other factors. This is typically achieved using three interconnected tools: control groups, placebos, and blinding. Together, these elements form the bedrock of modern evidence-based medicine, helping regulators determine whether a new treatment should be approved for public use.

The Role of Control Groups and Placebos

In a clinical trial, participants are usually divided into groups. One group receives the experimental medicine, while another group—known as the control group—receives a different intervention for comparison. Sometimes the control group receives a placebo, which is an inactive substance or sham procedure designed to look, taste, and feel exactly like the real medicine. By comparing the outcomes of the treatment group against the control group, researchers can determine whether any improvements are due to the medicine itself or merely the natural progression of the illness over time.

It is worth noting that control groups do not always receive a placebo. In many trials, the control group receives an active control, which is an established, proven treatment already on the market. This is often done to test whether the new medicine is better than, or at least as good as, the current standard of care.

Understanding the Placebo Effect

The placebo effect is a psychological and biological phenomenon where a patient experiences a perceived or actual improvement in their condition after receiving a placebo, simply because they expect the treatment to work. This effect can influence subjective symptoms like pain, fatigue, and nausea, and can sometimes trigger measurable physiological responses, such as changes in heart rate or brain chemistry.

Because the placebo effect can be remarkably strong, it complicates the assessment of a new medicine. If researchers gave everyone the new drug and a portion of the participants felt better, they would not know if the drug caused the improvement or if a placebo effect was responsible. Using a placebo control allows researchers to mathematically subtract the placebo effect, isolating the genuine pharmacological effect of the experimental medicine.

Blinding: Keeping Participants and Researchers in the Dark

Knowing whether one is receiving the real medicine or a placebo can significantly influence a participant's behaviour, symptom reporting, and perception of side effects. It can also subconsciously influence how researchers assess the participants. To prevent this bias, trials use a technique called blinding. In a single-blind trial, only the participants do not know which treatment they are receiving. In a double-blind trial—which is considered the gold standard for clinical research—neither the participants nor the researchers interacting with them know who is receiving the active drug versus the placebo.

Blinding ensures that when researchers ask participants about side effects or measure symptom relief, their own expectations do not colour the results. The codes assigning patients to the treatment or placebo groups are only broken after the trial has ended and the data has been fully collected and analysed.

The Ethics of Placebo Controls

While placebos are scientifically useful, their use raises important ethical questions. The foundational principle of medical research is that the well-being of the participant takes precedence over the interests of science or society. Generally, it is considered unethical to give a patient a placebo if an effective, proven treatment already exists for their condition. Denying a patient a known working therapy could lead to worsening symptoms or serious harm.

Placebo-controlled trials are therefore generally reserved for situations where no proven standard of care exists, or for minor, self-limiting conditions where withholding treatment does not pose a serious risk to the patient. Ethical guidelines, such as the Declaration of Helsinki, require that patients in the control group receive the best current treatment if one is available. Every clinical trial must be reviewed and approved by an ethics committee to ensure that the use of a placebo is justified.

Regulatory Oversight and Medicine Approval

Before a clinical trial can begin, it must be rigorously reviewed by regulatory authorities to ensure both scientific validity and participant safety. In South Africa, the South African Health Products Regulatory Authority (SAHPRA) oversees the approval and monitoring of clinical trials, ensuring that the use of placebos and blinding adheres to strict international ethical standards. Once a medicine successfully clears these trials and is registered, its approval status and pricing information can be verified by the public through tools like HealthSA.